October 31, 2013 / 10:19 AM / 4 years ago

Canada's Valeant Pharma posts quarterly net loss

1 Min Read

Oct 31 (Reuters) - Valeant Pharmaceuticals International Inc , Canada's biggest publicly traded drugmaker, posted a quarterly net loss that it attributed in part to restructuring and impairment charges.

Valeant posted a net loss of $973 million, or $2.92 per share, for the third quarter, compared with a profit of $7.6 million, or 2 cents, a year earlier.

Cash earnings, or profit adjusted for one-time items, was $486 million, or $1.43 per share.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below